Swedish Orphan Biovitrum AB (publ)
BIOVF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $105 | $86 | $68 | $57 |
| - Cash | $1 | $1 | $1 | $1 |
| + Debt | $17 | $20 | $9 | $11 |
| Enterprise Value | $120 | $106 | $76 | $67 |
| Revenue | $26 | $22 | $19 | $16 |
| % Growth | 17.6% | 17.7% | 21% | – |
| Gross Profit | $20 | $17 | $14 | $12 |
| % Margin | 77.8% | 77.4% | 74.6% | 77.6% |
| EBITDA | $9 | $7 | $6 | $6 |
| % Margin | 35.7% | 32.7% | 32.2% | 36.8% |
| Net Income | $4 | $2 | $3 | $3 |
| % Margin | 14.9% | 10.9% | 14% | 17.3% |
| EPS Diluted | 11.24 | 7.39 | 8.44 | 8.62 |
| % Growth | 52.1% | -12.4% | -2.1% | – |
| Operating Cash Flow | $7 | $4 | $5 | $5 |
| Capital Expenditures | -$3 | -$5 | -$1 | -$0 |
| Free Cash Flow | $4 | -$0 | $3 | $5 |